STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
| Revenue (TTM) | $339.59M |
| Gross Profit (TTM) | $260.20M |
| EBITDA | $49.76M |
| Operating Margin | 10.90% |
| Return on Equity | 1.09% |
| Return on Assets | 5.65% |
| Revenue/Share (TTM) | $6.80 |
| Book Value | $7.08 |
| Price-to-Book | 3.59 |
| Price-to-Sales (TTM) | 3.53 |
| EV/Revenue | 3.439 |
| EV/EBITDA | 23.00 |
| Quarterly Earnings Growth (YoY) | -10.50% |
| Quarterly Revenue Growth (YoY) | 111.00% |
| Shares Outstanding | $50.14M |
| Float | $26.14M |
| % Insiders | 0.83% |
| % Institutions | 111.76% |
Volatility is currently expanding
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111% Y/Y Net sales excluding China of $41.2 million, up 6.0% Y/Y China sales of $52.3 million up over 100%, 10% sequentially APAC sales up 189% Y/Y, ex-China sales up.
Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.Net sales for the second quarter of 2026 are expected to be in excess of.
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas.
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STAA and any ticker you trade — then tracks every position and per-strategy win rate.
